ENTA Enanta Pharmaceuticals, Inc. Net earnings per share growth forecast for next year

Symbol and logo of brand Enanta Pharmaceuticals (ENTA)

Enanta Pharmaceuticals (ENTA) is characterized by a transparent R&D pipeline and strict cost control. The GURU.Markets portal contains the history of changes in earnings per share expectations, where 4.20 reflects the baseline level of the metric. High barriers to entry create unique patent protections, while future revenues rely on the success of new developments and current royalties from hepatitis C treatment.

ENTA: Enanta Expected net earnings per share growth next year 07/04/2022 - 11/16/2026

Analytical breakdowns and data insights for company Enanta Pharmaceuticals Inc. (ENTA)

General company analysis:Enanta
Finished products of Enanta Pharmaceuticals, Inc.

This indicator is critical for filtering assets and stress-testing a portfolio for future returns. It captures the consensus forecast for earnings per share (EPS) changes, stripping analyst expectations of market noise and emotional volatility. The trend in projected EPS changes for the coming year reflects a fundamental revaluation of the business. For Enanta Pharmaceuticals (ENTA), this directly correlates with progress in developing protease inhibitors for the therapy of respiratory viruses.

Direct competitors

Expected earnings per share growth for next year GILD|Earnings growth forecast for next year Cidara Therapeutics, Inc.|Net earnings per share growth forecast for next year Novavax Inc (NVAX)|Consensus forecast of earnings per share growth for next year CureVac|Valneva Pharma - Expected earnings per share growth for next year|Consensus forecast of earnings per share growth for next year Vir Corp (VIR)|siga.com - Earnings growth forecast for next year|Expected net earnings per share growth next year emergentbiosolutions.com|AVIR: Earnings growth forecast for next year|IVVD (Invivyd Inc) - Net earnings per share growth forecast for next year|INO (Inovio Pharma) - Earnings growth forecast for next year|Net earnings per share growth forecast for next year HLVX|Net earnings per share growth forecast for next year Kalaris Therapeutics Inc (KLRS)|Consensus forecast of earnings per share growth for next year Dyadic International, Inc.|Earnings growth forecast for next year NNVC (nanoviricides.com)|Talphera Inc (TLPH) - Expected net earnings per share growth next year|COCP: Expected earnings per share growth for next year|Net earnings per share change forecast for next year TRAW|DWTX (Virios Therapeutics) - Expected earnings per share growth for next year|Projected earnings per share growth rate for next year QLGN|ALVR (AlloVir) - Earnings growth forecast for next year|vbivaccines.com (VBIV) - Consensus forecast of earnings per share growth for next year|Earnings growth forecast for next year VIRI|Expected earnings per share growth for next year Vaxart Corp VXRT